Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
September 2018
-
Media Release
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period … -
Media Release
Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the… -
Media Release
Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in… -
Media Release
Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease
If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease Children and adults… -
Media Release
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research[1] 79% are willing… -
Media Release
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos,… -
Media Release
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th… -
Media Release
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects… -
Media Release
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no… -
Media Release
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has… -
Media Release
Alcon confirme son engagement envers la Suisse en perspective de la scission proposée avec Novartis
Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon… -
Media Release
Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz
Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg…